PH 2 ADI-PEG 20 Acute Myeloid Leukemia
This trial is active, not recruiting.
|Condition||aml subjects who have failed prior systemic therapy|
|Start date||June 2012|
|End date||April 2017|
|Trial size||43 participants|
|Trial identifier||NCT01910012, POLARIS2012-001|
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Houston, TX||M D Anderson Cancer Center||no longer recruiting|
|Kaohsiung City, Taiwan||Kaohsiung Medical University Chung-Ho Memorial Hospital||no longer recruiting|
|Taichung, Taiwan||CMUH||no longer recruiting|
|Tainan City, Taiwan||NCKUH||no longer recruiting|
|Taoyuan, Taiwan||CGMH-LK||no longer recruiting|
|Intervention model||single group assignment|
arginine deiminase formulated with polyethlene glycol
time frame: 2 years estimated
Safety and tolerability
time frame: 2 years estimated
All participants at least 18 years old.
Inclusion Criteria: 1. Acute myeloid leukemia (AML) diagnosed by morphologic, histochemical or cell surface marker criteria. 2. Patients with AML must have either: (a) relapsed or refractory leukemia after receiving at least one prior conventional induction therapy. Those in early first relapse must not have a matched donor and/or they must not be a candidate for allogeneic stem cell transplantation (usually this would mean the patient is too ill, obese, has a co-morbid condition or is over the age of 55 years) or (b) poor-risk AML as defined below: (i) Treatment related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t(16;16), t(8;21), t(15;17), and not a candidate for stem cell transplantation, or (ii) AML with an antecedent hematologic disease (e.g., MDS, myelofibrosis, polycythemia vera, etc.), and not a candidate for stem cell transplantation. (iii) De novo AML > 70 years of age. (iv) AML with unfavorable cytogenetics regardless of age (>18 years), if patients are not candidates for allogeneic transplantation. Unfavorable cytogenetics are the following: complex (>3 abnormalities), -7, -5, 7q-, 5q-, abnormalities of 11q23 excluding t(9;11), t(9;22), inversion 3, t(3;3), t(6;9). (c) Patients older than 60 years of age who had AML (i.e., > 20% bone marrow blasts) and no prior therapy for AML 3. Age ≥ 18 years. 4. ECOG performance status of 0-2. 5. Post-menarche female subjects and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study. Subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study. Females must not be pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study. Exclusion Criteria: 1. Patients with infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study; patients on prophylactic antibiotics or antivirals are acceptable. 2. Pregnancy or lactation. 3. Expected non-compliance. 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, psychiatric illness, social situations that would limit compliance with study requirements or DIC. 5. Subjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or≤ Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both. 6. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the investigator will not affect patient outcome in the setting of current diagnosis.
|Official title||Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia|
Call for more information